Outcomes. N = 18 patients with median follow-up of 14.0 months. (A) Kaplan-Meier survival probabilities overall survival (solid line) and progression-free survival (PFS; dashed line). OS was measured from stem cell infusion to death from any cause. PFS was defined as time from stem cell infusion to recurrence, progression, or death from any cause, whichever occurred first. (B) Cumulative incidence of relapse/progression (RPR; dashed line) and nonrelapse mortality (NRM; solid line), calculated as competing risks. The cumulative incidence of relapse/progression (RP) was defined as time from stem cell infusion to recurrence or progression. Nonrelapse mortality (NRM) was measured from transplant to death from any cause other than disease relapse or progression.